A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet’s syndrome

Abstract Infliximab (IFX) was the first biologic introduced for refractory uveitis treatment in Behçet’s syndrome (BS). However, there have been few reports on the safety and efficacy of IFX monotherapy over follow-up periods of more than 10 years. This retrospective study evaluated the 10-year safe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Noe Horiguchi, Koju Kamoi, Shintaro Horie, Yuko Iwasaki, Hisako Kurozumi-Karube, Hiroshi Takase, Kyoko Ohno-Matsui
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
R
Q
Acceso en línea:https://doaj.org/article/c2c6986109f94e438d98391d829b7e87
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares